O	0	8	Combined
O	9	17	clinical
O	18	23	trial
O	24	31	results
O	32	34	of
O	35	36	a
B-intervention	37	41	HER2
I-intervention	41	42	/
I-intervention	42	45	neu
I-intervention	46	47	(
I-intervention	47	50	E75
I-intervention	50	51	)
I-intervention	52	59	vaccine
O	60	63	for
O	64	67	the
O	68	78	prevention
O	79	81	of
O	82	92	recurrence
O	93	95	in
O	96	100	high
O	100	101	-
O	101	105	risk
O	106	112	breast
O	113	119	cancer
O	120	128	patients
O	128	129	:
B-location	130	131	U
I-location	131	132	.
I-location	132	133	S
O	133	134	.

O	135	143	Military
O	144	150	Cancer
O	151	160	Institute
O	161	169	Clinical
O	170	176	Trials
O	177	182	Group
O	183	188	Study
O	189	190	I
O	190	191	-
O	191	193	01
O	194	197	and
O	198	199	I
O	199	200	-
O	200	202	02
O	202	203	.

O	204	207	E75
O	208	210	is
O	211	213	an
O	214	225	immunogenic
O	226	233	peptide
O	234	238	from
O	239	242	the
O	243	247	HER2
O	247	248	/
O	248	251	neu
O	252	259	protein
O	259	260	,
O	261	266	which
O	267	269	is
O	270	283	overexpressed
O	284	286	in
O	287	291	many
O	292	298	breast
O	299	305	cancer
O	306	314	patients
O	314	315	.

O	316	318	We
O	319	323	have
O	324	333	conducted
O	334	337	two
O	338	349	overlapping
O	350	353	E75
O	354	361	vaccine
O	362	368	trials
O	369	371	to
O	372	379	prevent
O	380	390	recurrence
O	391	393	in
B-eligibility	394	398	node
I-eligibility	398	399	-
I-eligibility	399	407	positive
I-eligibility	408	409	(
I-eligibility	409	411	NP
I-eligibility	411	412	)
I-eligibility	413	416	and
I-eligibility	417	421	node
I-eligibility	421	422	-
I-eligibility	422	430	negative
I-eligibility	431	432	(
I-eligibility	432	434	NN
I-eligibility	434	435	)
I-eligibility	436	442	breast
I-eligibility	443	449	cancer
I-eligibility	450	458	patients
O	458	459	.

O	460	463	E75
O	464	465	(
O	465	469	HER2
O	469	470	/
O	470	473	neu
O	474	477	369
O	477	478	-
O	478	481	377
O	481	482	)
O	483	484	+
O	485	496	granulocyte
O	497	507	macrophage
O	508	514	colony
O	514	515	-
O	515	526	stimulating
O	527	533	factor
O	534	537	was
O	538	543	given
O	544	557	intradermally
O	558	560	to
O	561	571	previously
O	572	579	treated
O	579	580	,
O	581	588	disease
O	588	589	-
O	589	593	free
O	594	596	NP
O	597	603	breast
O	604	610	cancer
O	611	619	patients
O	620	622	in
O	623	624	a
O	625	629	dose
O	630	640	escalation
O	641	647	safety
O	648	653	trial
O	654	657	and
O	658	660	to
O	661	663	NN
O	664	670	breast
O	671	677	cancer
O	678	686	patients
O	687	689	in
O	690	691	a
O	692	696	dose
O	697	709	optimization
O	710	715	study
O	715	716	.

O	717	722	Local
O	723	726	and
O	727	735	systemic
O	736	744	toxicity
O	745	748	was
O	749	758	monitored
O	758	759	.

O	760	771	Immunologic
O	772	781	responses
O	782	786	were
O	787	795	assessed
O	796	801	using
O	802	804	in
O	805	810	vitro
O	811	817	assays
O	818	821	and
O	822	824	in
O	825	829	vivo
O	830	837	delayed
O	837	838	-
O	838	842	type
O	843	859	hypersensitivity
O	860	869	responses
O	869	870	.

O	871	879	Clinical
O	880	891	recurrences
O	892	896	were
O	897	907	documented
O	907	908	.

B-total-participants	909	912	One
I-total-participants	913	920	hundred
I-total-participants	921	924	and
I-total-participants	925	931	eighty
I-total-participants	931	932	-
I-total-participants	932	935	six
O	936	944	patients
O	945	949	were
O	950	958	enrolled
O	959	961	in
O	962	965	the
O	966	969	two
O	970	977	studies
O	978	979	(
O	979	981	NP
O	981	982	,
O	983	985	95
O	985	986	;
O	987	989	NN
O	989	990	,
O	991	993	91
O	993	994	)
O	994	995	.

O	996	1001	Human
O	1002	1011	leucocyte
O	1012	1019	antigen
O	1020	1022	A2
O	1023	1024	(
O	1024	1027	HLA
O	1027	1028	-
O	1028	1030	A2
O	1030	1031	)
O	1032	1035	and
O	1036	1039	HLA
O	1039	1040	-
O	1040	1042	A3
O	1043	1051	patients
O	1052	1056	were
O	1057	1067	vaccinated
O	1068	1069	(
O	1069	1070	n
O	1071	1072	=
B-intervention-participants	1073	1076	101
O	1076	1077	)
O	1077	1078	,
O	1079	1086	whereas
O	1087	1090	all
O	1091	1097	others
O	1098	1099	(
O	1099	1100	n
O	1101	1102	=
B-control-participants	1103	1105	85
O	1105	1106	)
O	1107	1111	were
O	1112	1120	followed
O	1121	1134	prospectively
O	1135	1137	as
B-control	1138	1146	controls
O	1146	1147	.

O	1148	1158	Toxicities
O	1159	1163	were
O	1164	1171	minimal
O	1171	1172	,
O	1173	1176	and
O	1177	1178	a
O	1179	1183	dose
O	1183	1184	-
O	1184	1193	dependent
O	1194	1205	immunologic
O	1206	1214	response
O	1215	1217	to
O	1218	1221	the
O	1222	1229	vaccine
O	1230	1233	was
O	1234	1239	shown
O	1239	1240	.

O	1241	1248	Planned
O	1249	1256	primary
O	1257	1265	analysis
O	1266	1274	revealed
O	1275	1276	a
B-outcome	1277	1287	recurrence
I-outcome	1288	1292	rate
O	1293	1295	of
B-iv-bin-percent	1296	1297	5
I-iv-bin-percent	1297	1298	.
I-iv-bin-percent	1298	1299	6
I-iv-bin-percent	1299	1300	%
O	1301	1303	in
O	1304	1314	vaccinated
O	1315	1323	patients
O	1324	1332	compared
O	1333	1337	with
B-cv-bin-percent	1338	1340	14
I-cv-bin-percent	1340	1341	.
I-cv-bin-percent	1341	1342	2
I-cv-bin-percent	1342	1343	%
O	1344	1346	in
O	1347	1350	the
O	1351	1359	controls
O	1360	1361	(
O	1361	1362	P
O	1363	1364	=
O	1365	1366	0
O	1366	1367	.
O	1367	1369	04
O	1369	1370	)
O	1371	1373	at
O	1374	1375	a
O	1376	1382	median
O	1383	1385	of
O	1386	1388	20
O	1389	1395	months
O	1396	1402	follow
O	1402	1403	-
O	1403	1405	up
O	1405	1406	.

O	1407	1409	As
O	1410	1417	vaccine
O	1417	1418	-
O	1418	1426	specific
O	1427	1435	immunity
O	1436	1441	waned
O	1442	1446	over
O	1447	1451	time
O	1451	1452	,
O	1453	1456	the
B-outcome	1457	1467	difference
I-outcome	1468	1470	in
I-outcome	1471	1481	recurrence
O	1482	1486	lost
O	1487	1499	significance
O	1500	1502	at
O	1503	1505	26
O	1506	1512	months
O	1513	1519	median
O	1520	1526	follow
O	1526	1527	-
O	1527	1529	up
O	1530	1531	(
B-iv-bin-percent	1531	1532	8
I-iv-bin-percent	1532	1533	.
I-iv-bin-percent	1533	1534	3
I-iv-bin-percent	1534	1535	%
O	1536	1542	versus
B-cv-bin-percent	1543	1545	14
I-cv-bin-percent	1545	1546	.
I-cv-bin-percent	1546	1547	8
I-cv-bin-percent	1547	1548	%
O	1548	1549	)
O	1549	1550	;
O	1551	1558	however
O	1558	1559	,
O	1560	1561	a
O	1562	1573	significant
O	1574	1584	difference
O	1585	1587	in
O	1588	1591	the
O	1592	1599	pattern
O	1600	1602	of
O	1603	1613	recurrence
O	1614	1623	persisted
O	1623	1624	.

O	1625	1628	E75
O	1629	1631	is
B-outcome	1632	1636	safe
I-outcome	1637	1640	and
I-outcome	1641	1650	effective
O	1651	1653	in
O	1654	1661	raising
O	1662	1663	a
O	1664	1668	dose
O	1668	1669	-
O	1669	1678	dependent
O	1679	1683	HER2
O	1683	1684	/
O	1684	1687	neu
O	1688	1696	immunity
O	1697	1699	in
O	1700	1703	HLA
O	1703	1704	-
O	1704	1706	A2
O	1707	1710	and
O	1711	1714	HLA
O	1714	1715	-
O	1715	1717	A3
O	1718	1720	NP
O	1721	1724	and
O	1725	1727	NN
O	1728	1734	breast
O	1735	1741	cancer
O	1742	1750	patients
O	1750	1751	.

O	1752	1756	More
O	1757	1768	importantly
O	1768	1769	,
O	1770	1773	E75
O	1774	1777	may
O	1778	1784	reduce
B-outcome	1785	1796	recurrences
I-outcome	1797	1799	in
I-outcome	1800	1807	disease
I-outcome	1807	1808	-
I-outcome	1808	1812	free
O	1812	1813	,
O	1814	1828	conventionally
O	1829	1836	treated
O	1836	1837	,
O	1838	1842	high
O	1842	1843	-
O	1843	1847	risk
O	1848	1854	breast
O	1855	1861	cancer
O	1862	1870	patients
O	1870	1871	.

O	1872	1877	These
O	1878	1886	findings
O	1887	1894	warrant
O	1895	1896	a
O	1897	1908	prospective
O	1908	1909	,
O	1910	1920	randomized
O	1921	1926	phase
O	1927	1930	III
O	1931	1936	trial
O	1937	1939	of
O	1940	1943	the
O	1944	1947	E75
O	1948	1955	vaccine
O	1956	1960	with
O	1961	1969	periodic
O	1970	1977	booster
O	1978	1980	to
O	1981	1988	prevent
O	1989	1995	breast
O	1996	2002	cancer
O	2003	2014	recurrences
O	2014	2015	.
